查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930113

流感治疗药物市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察，2026-2034 年

Influenza Medication Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 145 Pages | 商品交期: 请询问到货日

价格

流感治疗药物市场成长驱动因素

全球流感治疗药物市场在控制世界上最广泛传播且最具传染性的传染病之一—流感方面发挥着至关重要的作用。由于病毒株的不断演变、季节性流行以及老年人、孕妇和免疫功能低下者等高危险群的存在，流感仍然是一项严峻的公共卫生挑战。公众意识的提高、诊断技术的进步以及先进抗病毒疗法的出现是塑造市场格局的关键因素。

市场规模及预测

根据 Fortune Business Insights 的数据，2025 年全球流感治疗市场规模为 9.6 亿美元。预计到 2026 年将成长至 9.9 亿美元，到 2034 年将达到 71.5 亿美元，预测期内复合年增长率高达 14.25%。

这种强劲成长主要归功于流感流行频率的增加、病毒变异、诊断率的提高以及新一代抗病毒药物的广泛应用。

市场概览

过去几十年，全球流感流行呈现持续上升趋势。美国每年爆发的流感疫情以及亚洲和欧洲的反覆爆发都大大促进了市场扩张。根据美国疾病管制与预防中心 (CDC) 统计，自 2019 年 10 月以来，美国已报告约 970 万例流感病例，凸显了流感持续带来的沉重疾病负担。

虽然季节性流感疫苗被广泛使用，但由于病毒的基因变异性，疫苗并非总是完全有效，因此对有效抗病毒药物的需求日益增长。

主要市场驱动因子

流感治疗市场的主要驱动因素之一是人们对流感严重性和併发症的认识不断提高。美国疾病管制与预防中心 (CDC) 和世界卫生组织 (WHO) 等政府医疗机构正在积极进行宣传活动，以促进早期诊断和治疗。

另一个主要驱动因素是旨在开发新疗法的研发活动的增加。儘管患者人数不断增长，但目前获得美国食品药物管理局 (FDA) 批准的流感治疗药物数量有限，造成了巨大的未满足需求。巴洛沙韦酯（Xofluza）等药物的上市为流感治疗带来了新的选择，并提高了疗效。

诊断技术进步的作用

快速流感诊断测试（RIDT）是市场成长的重要推手。这些测试可以检测甲型和乙型流感抗原，并在 5 至 15 分钟内提供结果。近期监管法规的变更将 RIDT 从 I 类医疗器械重新归类为 II 类医疗器械，提高了其准确性，从而提高了诊断率，并促进了流感治疗的更广泛应用。

市场区隔分析

依治疗方法划分

根据治疗方法，市场可细分为磷酸奥司他韦、巴洛沙韦酯和其他药物。

由于奥司他韦磷酸酯的广泛应用和确切疗效，预计到2026年，其市场占有率将达到57.44%，占市场主导地位。然而，由于专利到期和仿製药竞争，其成长速度正在放缓。

巴洛沙韦酯市场预计将以最高的复合年增长率成长，这得益于近期在美国和日本等主要市场的上市。

依流感类型划分

依流感类型划分，市场分为甲型流感和乙型流感。

由于甲型流感的高盛行率以及与大规模疫情的关联，预计到2026年，甲型流感将占75.82%的市场占有率。乙型流感在某些流感季也会对市场成长做出贡献。

依给药途径

口服给药途径占市场主导地位，预计到2026年将占95.02%的市场占有率，这主要得益于其给药方便以及达菲（Tamiflu）和舒氟沙星（Xofluza）等药物的广泛应用。

按分销管道

医院药局占最大的市场占有率，这主要得益于诊断处方。零售药房位居第二，而线上药房预计将凭藉数位化发展实现最高的复合年增长率。

按地区分析

北美地区在流感治疗市场中占主导地位，2025 年市占率达到 59.56%，预计 2026 年市场收入将达到 5.9 亿美元。光是美国市场预计到 2026 年就将达到 5.5 亿美元。

亚太地区预计将实现最快成长，预计到 2026 年，日本市场规模将达到 7,000 万美元，中国达到 5,000 万美元，印度达到 2,000 万美元。欧洲流感活动的增加也推动了市场的稳定成长。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇

第四章：关键考虑因素

  • 流感流行病学概述
  • 主要地区流感疾病负担分析
  • 新产品上市
  • 在开发产品分析
  • 仿製药上市对流感治疗市场的影响分析
  • 主要行业趋势

第五章：全球流感治疗市场分析、洞察与预测 （2021-2034）

  • 主要发现/摘要
  • 市场分析、洞察与预测 - 按疗法划分
    • 巴洛沙韦酯
    • 磷酸奥司他韦
    • 其他
  • 市场分析、洞察与预测 - 按流感类型划分
    • 甲型流感
    • B型流感
  • 市场分析、洞察与预测 - 按给药途径划分
    • 口服
    • 其他
  • 市场分析、洞察与预测 - 按分销管道划分
    • 医院药房
    • 零售药房
    • 线上药房
    • 其他
  • 市场分析、洞察与预测 - 按区域
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美流感治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲流感治疗市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 其他地区欧洲

第8章 亚太地区的流感治疗药市场分析，洞察与预测(2021～2034年)

  • 各国
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 其他的亚太地区

第9章 南美的流感治疗药市场分析，洞察与预测(2021～2034年)

  • 各国
    • 巴西
    • 墨西哥
    • 其他的南美

第10章 中东·非洲的流感治疗药市场分析，洞察与预测(2021～2034年)

  • 各国
    • GCC
    • 南非
    • 其他的中东·非洲

第11章 竞争分析

  • 主要产业趋势
  • 全球市场占有率分析(2025年)
  • 竞争形势仪表板
  • 主要企业比较分析
  • 企业简介
    • Genentech, Inc.
    • Shionogi & Co., Ltd.
    • Seqirus(CSL)
    • BIOCRYST PHARMACEUTICALS, INC.
    • GlaxoSmithKline plc
    • Lupin Limited
    • Teva Pharmaceutical Industries Ltd.
    • Zydus Pharmaceuticals, Inc.(Zydus Cadila)
    • Amneal Pharmaceuticals LLC
    • Macleods Pharmaceuticals Ltd.
    • Alvogen
    • 其他

第12章 策略性建议

Product Code: FBI101843

Growth Factors of influenza medication Market

The global influenza medication market plays a critical role in managing one of the most widespread and contagious infectious diseases worldwide. Influenza continues to pose a serious public health challenge due to its evolving viral strains, seasonal epidemics, and high-risk populations such as the elderly, pregnant women, and immunocompromised individuals. Growing awareness, improved diagnostics, and the launch of advanced antiviral therapies are key factors shaping the market landscape.

Market Size and Forecast

According to Fortune Business Insights, the global influenza medication market size was valued at USD 0.96 billion in 2025. The market is projected to grow to USD 0.99 billion in 2026 and reach USD 7.15 billion by 2034, registering a strong CAGR of 14.25% during the forecast period.

This robust growth is primarily attributed to the increasing frequency of influenza outbreaks, virus mutation, rising diagnosis rates, and growing adoption of next-generation antiviral drugs.

Market Overview

Influenza has shown a steady increase in global prevalence over the past few decades. Annual epidemics in countries such as the United States and recurring outbreaks across Asia and Europe significantly contribute to market expansion. According to the Centers for Disease Control and Prevention (CDC), an estimated 9.7 million influenza cases were reported in the U.S. since October 2019, highlighting the ongoing disease burden.

Although seasonal influenza vaccines are widely used, they are not always fully effective due to the genetic variability of the virus, increasing the need for effective antiviral medications.

Key Market Drivers

One of the primary drivers of the influenza medication market is increased awareness regarding the severity of influenza and its complications. Government and healthcare organizations such as the CDC and WHO actively conduct awareness campaigns, encouraging early diagnosis and treatment.

Another major driver is increased R&D activity aimed at developing novel therapeutics. Despite the growing patient population, only a limited number of FDA-approved influenza drugs are currently available, creating a large unmet treatment need. The launch of drugs such as Baloxavir Marboxil (Xofluza) has introduced new treatment options with improved efficacy.

Role of Diagnostic Advancements

Rapid Influenza Diagnostic Tests (RIDTs) have significantly influenced market growth. These tests detect influenza A and B antigens and deliver results within 5-15 minutes. Recent regulatory changes reclassifying RIDTs from Class I to Class II devices have improved their accuracy, leading to higher diagnosis rates and increased adoption of influenza medications.

Market Segmentation Analysis

By Treatment Type

Based on treatment, the market is segmented into oseltamivir phosphate, baloxavir marboxil, and others.

The oseltamivir phosphate segment dominated the market with a 57.44% share in 2026, driven by its widespread prescription and proven efficacy. However, growth is moderated due to patent expiration and generic competition.

The baloxavir marboxil segment is expected to grow at the highest CAGR, supported by recent launches in key markets such as the U.S. and Japan.

By Influenza Type

By influenza type, the market is segmented into influenza A and influenza B.

The influenza A segment accounted for 75.82% market share in 2026, owing to its high prevalence and association with major outbreaks. Influenza B also contributes to market growth during certain flu seasons.

By Route of Administration

The oral route dominated the market, accounting for 95.02% share in 2026, due to ease of administration and widespread use of drugs such as Tamiflu and Xofluza.

By Distribution Channel

The hospital pharmacies segment held the largest market share, supported by diagnosis-based prescriptions. Retail pharmacies ranked second, while online pharmacies are expected to witness the highest CAGR due to growing digital adoption.

Regional Analysis

North America dominated the influenza medication market with a 59.56% share in 2025 and generated USD 0.59 billion in revenue in 2026. The U.S. market alone is projected to reach USD 0.55 billion by 2026.

The Asia-Pacific region is expected to register the fastest growth, with Japan reaching USD 0.07 billion, China USD 0.05 billion, and India USD 0.02 billion by 2026. Europe is also witnessing rising influenza activity, supporting steady market growth.

Competitive Landscape

The market is led by key players such as Genentech, Inc., Shionogi & Co., Ltd., GlaxoSmithKline plc, Seqirus (CSL), and BioCryst Pharmaceuticals, Inc. The presence of generics makes the market mature and competitive, creating barriers for new entrants.

Conclusion

In conclusion, the global influenza medication market is poised for significant growth from USD 0.96 billion in 2025 to USD 7.15 billion by 2034, driven by rising influenza prevalence, improved diagnostics, strong R&D pipelines, and growing awareness initiatives. While generic competition remains a challenge, the introduction of advanced antiviral therapies and expanding healthcare access worldwide will continue to support long-term market expansion.

Segmentation By Treatment

  • Baloxavir marboxil
  • Oseltamivir phosphate
  • Others

By Influenza Type

  • Influenza A
  • Influenza B

By Route of Administration

  • Oral
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Overview of Influenza Epidemiology
  • 4.2. Analysis of Disease Burden of Influenza, By Key Regions
  • 4.3. New Product Launches
  • 4.4. Pipeline Analysis
  • 4.5. Analysis of the Impact of the Launch of Generics on the Influenza Medication Market
  • 4.6. Key Industry Developments

5. Global Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Treatment
    • 5.2.1. Baloxavir marboxil
    • 5.2.2. Oseltamivir phosphate
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Influenza Type
    • 5.3.1. Influenza A
    • 5.3.2. Influenza B
  • 5.4. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.4.1. Oral
    • 5.4.2. Others
  • 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.5.1. Hospital Pharmacies
    • 5.5.2. Retail Pharmacies
    • 5.5.3. Online Pharmacies
    • 5.5.4. Others
  • 5.6. Market Analysis, Insights and Forecast - By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Treatment
    • 6.2.1. Baloxavir marboxil
    • 6.2.2. Oseltamivir phosphate
    • 6.2.3. Others
  • 6.3. Market Analysis - By Influenza Type
    • 6.3.1. Influenza A
    • 6.3.2. Influenza B
  • 6.4. Market Analysis - By Route of Administration
    • 6.4.1. Oral
    • 6.4.2. Others
  • 6.5. Market Analysis - By Distribution Channel
    • 6.5.1. Hospital Pharmacies
    • 6.5.2. Retail Pharmacies
    • 6.5.3. Online Pharmacies
    • 6.5.4. Others
  • 6.6. Market Analysis - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Treatment
    • 7.2.1. Baloxavir marboxil
    • 7.2.2. Oseltamivir phosphate
    • 7.2.3. Others
  • 7.3. Market Analysis - By Influenza Type
    • 7.3.1. Influenza A
    • 7.3.2. Influenza B
  • 7.4. Market Analysis - By Route of Administration
    • 7.4.1. Oral
    • 7.4.2. Others
  • 7.5. Market Analysis - By Distribution Channel
    • 7.5.1. Hospital Pharmacies
    • 7.5.2. Retail Pharmacies
    • 7.5.3. Online Pharmacies
    • 7.5.4. Others
  • 7.6. Market Analysis - By Country/Sub-Region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Treatment
    • 8.2.1. Baloxavir marboxil
    • 8.2.2. Oseltamivir phosphate
    • 8.2.3. Others
  • 8.3. Market Analysis - By Influenza Type
    • 8.3.1. Influenza A
    • 8.3.2. Influenza B
  • 8.4. Market Analysis - By Route of Administration
    • 8.4.1. Oral
    • 8.4.2. Others
  • 8.5. Market Analysis - By Distribution Channel
    • 8.5.1. Hospital Pharmacies
    • 8.5.2. Retail Pharmacies
    • 8.5.3. Online Pharmacies
    • 8.5.4. Others
  • 8.6. Market Analysis - By Country/Sub-Region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Treatment
    • 9.2.1. Baloxavir marboxil
    • 9.2.2. Oseltamivir phosphate
    • 9.2.3. Others
  • 9.3. Market Analysis - By Influenza Type
    • 9.3.1. Influenza A
    • 9.3.2. Influenza B
  • 9.4. Market Analysis - By Route of Administration
    • 9.4.1. Oral
    • 9.4.2. Others
  • 9.5. Market Analysis - By Distribution Channel
    • 9.5.1. Hospital Pharmacies
    • 9.5.2. Retail Pharmacies
    • 9.5.3. Online Pharmacies
    • 9.5.4. Others
  • 9.6. Market Analysis - By Country/Sub-Region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Influenza Medication Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Treatment
    • 10.2.1. Baloxavir marboxil
    • 10.2.2. Oseltamivir phosphate
    • 10.2.3. Others
  • 10.3. Market Analysis - By Influenza Type
    • 10.3.1. Influenza A
    • 10.3.2. Influenza B
  • 10.4. Market Analysis - By Route of Administration
    • 10.4.1. Oral
    • 10.4.2. Others
  • 10.5. Market Analysis - By Distribution Channel
    • 10.5.1. Hospital Pharmacies
    • 10.5.2. Retail Pharmacies
    • 10.5.3. Online Pharmacies
    • 10.5.4. Others
  • 10.6. Market Analysis - By Country/ Sub-Region
    • 10.6.1. GCC Countries
    • 10.6.2. South Africa
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2025)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles
    • 11.5.1. Genentech, Inc.
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & Services,
      • 11.5.1.3. SWOT Analysis,
      • 11.5.1.4. Recent Developments,
      • 11.5.1.5. Strategies,
      • 11.5.1.6. Financials (Based On Availability)
    • 11.5.2. Shionogi & Co., Ltd.
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & Services,
      • 11.5.2.3. SWOT Analysis,
      • 11.5.2.4. Recent Developments,
      • 11.5.2.5. Strategies,
      • 11.5.2.6. Financials (Based On Availability)
    • 11.5.3. Seqirus (CSL)
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & Services,
      • 11.5.3.3. SWOT Analysis,
      • 11.5.3.4. Recent Developments,
      • 11.5.3.5. Strategies,
      • 11.5.3.6. Financials (Based On Availability)
    • 11.5.4. BIOCRYST PHARMACEUTICALS, INC.
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & Services,
      • 11.5.4.3. SWOT Analysis,
      • 11.5.4.4. Recent Developments,
      • 11.5.4.5. Strategies,
      • 11.5.4.6. Financials (Based On Availability)
    • 11.5.5. GlaxoSmithKline plc
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & Services,
      • 11.5.5.3. SWOT Analysis,
      • 11.5.5.4. Recent Developments,
      • 11.5.5.5. Strategies,
      • 11.5.5.6. Financials (Based On Availability)
    • 11.5.6. Lupin Limited
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & Services,
      • 11.5.6.3. SWOT Analysis,
      • 11.5.6.4. Recent Developments,
      • 11.5.6.5. Strategies,
      • 11.5.6.6. Financials (Based On Availability)
    • 11.5.7. Teva Pharmaceutical Industries Ltd.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & Services,
      • 11.5.7.3. SWOT Analysis,
      • 11.5.7.4. Recent Developments,
      • 11.5.7.5. Strategies,
      • 11.5.7.6. Financials (Based On Availability)
    • 11.5.8. Zydus Pharmaceuticals, Inc. (Zydus Cadila)
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & Services,
      • 11.5.8.3. SWOT Analysis,
      • 11.5.8.4. Recent Developments,
      • 11.5.8.5. Strategies,
      • 11.5.8.6. Financials (Based On Availability)
    • 11.5.9. Amneal Pharmaceuticals LLC
      • 11.5.9.1. Overview,
      • 11.5.9.2. Products & Services,
      • 11.5.9.3. SWOT Analysis,
      • 11.5.9.4. Recent Developments,
      • 11.5.9.5. Strategies,
      • 11.5.9.6. Financials (Based On Availability)
    • 11.5.10. Macleods Pharmaceuticals Ltd.
      • 11.5.10.1. Overview,
      • 11.5.10.2. Products & Services,
      • 11.5.10.3. SWOT Analysis,
      • 11.5.10.4. Recent Developments,
      • 11.5.10.5. Strategies,
      • 11.5.10.6. Financials (Based On Availability)
    • 11.5.11. Alvogen
      • 11.5.11.1. Overview,
      • 11.5.11.2. Products & Services,
      • 11.5.11.3. SWOT Analysis,
      • 11.5.11.4. Recent Developments,
      • 11.5.11.5. Strategies,
      • 11.5.11.6. Financials (Based On Availability)
    • 11.5.12. Others
      • 11.5.12.1. Overview,
      • 11.5.12.2. Products & Services,
      • 11.5.12.3. SWOT Analysis,
      • 11.5.12.4. Recent Developments,
      • 11.5.12.5. Strategies,
      • 11.5.12.6. Financials (Based On Availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 2: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 3: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 4: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 5: Global Influenza Medication Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 6: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 7: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 8: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 9: North America Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 10: North America Influenza Medication Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 11: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 12: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 13: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 14: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 15: Europe Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 17: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 18: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 19: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Asia Pacific Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 22: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 23: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 24: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Latin America Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Treatment, 2021-2034
  • Table 27: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Influenza Type, 2021-2034
  • Table 28: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Route of Administration, 2021-2034
  • Table 29: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 30: Middle East & Africa Influenza Medication Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Influenza Medication Market Revenue Breakdown (US$ Mn, %) by Region, 2025-2034
  • Figure 2: Global Influenza Medication Market Value Share (%), by Treatment, 2025-2034
  • Figure 3: Global Influenza Medication Market Forecast (US$ Mn), by Baloxavir marboxil, 2021-2034
  • Figure 4: Global Influenza Medication Market Forecast (US$ Mn), by Oseltamivir phosphate, 2021-2034
  • Figure 5: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 6: Global Influenza Medication Market Value Share (%), by Influenza Type, 2025-2034
  • Figure 7: Global Influenza Medication Market Forecast (US$ Mn), by Influenza A, 2021-2034
  • Figure 8: Global Influenza Medication Market Forecast (US$ Mn), by Influenza B, 2021-2034
  • Figure 9: Global Influenza Medication Market Value Share (%), by Route of Administration, 2025-2034
  • Figure 10: Global Influenza Medication Market Forecast (US$ Mn), by Oral, 2021-2034
  • Figure 11: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 12: Global Influenza Medication Market Value Share (%), by Distribution Channel, 2025-2034
  • Figure 13: Global Influenza Medication Market Forecast (US$ Mn), by Hospital Pharmacies, 2021-2034
  • Figure 14: Global Influenza Medication Market Forecast (US$ Mn), by Retail Pharmacies, 2021-2034
  • Figure 15: Global Influenza Medication Market Forecast (US$ Mn), by Online Pharmacies, 2021-2034
  • Figure 16: Global Influenza Medication Market Forecast (US$ Mn), by Others, 2021-2034
  • Figure 17: Global Influenza Medication Market Value (US$ Mn), by Region, 2025-2034
  • Figure 18: North America Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 19: North America Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 20: North America Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 21: North America Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 22: North America Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 23: North America Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 24: North America Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 25: North America Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 26: North America Influenza Medication Market Value (US$ Mn), By Country, 2025-2034
  • Figure 27: North America Influenza Medication Market Value Share (%), By Country, 2025
  • Figure 28: Europe Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 29: Europe Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 30: Europe Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 31: Europe Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 32: Europe Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 33: Europe Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Europe Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 35: Europe Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Europe Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 37: Europe Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Asia Pacific Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 39: Asia Pacific Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 40: Asia Pacific Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 41: Asia Pacific Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 42: Asia Pacific Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 43: Asia Pacific Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 44: Asia Pacific Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 45: Asia Pacific Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 46: Asia Pacific Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 47: Asia Pacific Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 48: Latin America Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 49: Latin America Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 50: Latin America Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 51: Latin America Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 52: Latin America Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 53: Latin America Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 54: Latin America Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 55: Latin America Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 56: Latin America Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 57: Latin America Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 58: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Treatment, 2025-2034
  • Figure 59: Middle East & Africa Influenza Medication Market Value Share (%), by Treatment, 2025
  • Figure 60: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Influenza Type, 2025-2034
  • Figure 61: Middle East & Africa Influenza Medication Market Value Share (%), by Influenza Type, 2025
  • Figure 62: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Route of Administration, 2025-2034
  • Figure 63: Middle East & Africa Influenza Medication Market Value Share (%), by Route of Administration, 2025
  • Figure 64: Middle East & Africa Influenza Medication Market Value (US$ Mn), by Distribution Channel, 2025-2034
  • Figure 65: Middle East & Africa Influenza Medication Market Value Share (%), by Distribution Channel, 2025
  • Figure 66: Middle East & Africa Influenza Medication Market Value (US$ Mn), By Country/ Sub-region, 2025-2034
  • Figure 67: Middle East & Africa Influenza Medication Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Influenza Medication Market Share (%), By Company, 2025